This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
The effectiveness data from which the model inputs were derived came from a clinical trial, full details of which were presented in the paper. The transition probability for all-cause mortality was derived using data from the Central Office of Statistics in the Netherlands.
Methods used to judge relevance and validity, and for extracting data
The aim of the model was to extrapolate the findings of a clinical trial, therefore no review took place. The use of mortality statistics was necessary to facilitate the extrapolation and the source was justified given the location of the study.
Measure of benefits used in the economic analysis
The authors used quality-adjusted life-years (QALYs) as a measure of benefit. The quality of life (utility) associated with disease management and usual care was measured using the EQ-5D. With the exception of the "death" state, all health states were assigned a specific utility value obtained from the underlying data set. The utilities were reported in a supplementary web table. The benefits were discounted at an annual rate of 4%.
Direct costs
Data collected in the 3-month pre-measurement period were used to estimate resource use within usual care. The data collected at the 1-year follow-up were used to represent resource use within the DMP. The data were seasonally adjusted. The health-related direct costs covered planned consultations with GP, RNS and pulmonologist, non-routine consultations due to an exacerbation, maintenance and emergency medication used, and hospital admissions. Overhead costs were also included. These comprised the costs of employing a medical and project coordinator, continuing education of the RNSs, an administrative support office, maintenance of the electronic patient record system used by the RNSs, telephone and travel for RNSs, and the salary of the unit leader. Training costs of RNSs were not considered because they were already employed in the health care system; learning costs were also not taken into account. The direct costs were discounted at an annual rate of 4%. Details of the direct cost data were presented in a supplementary web table.
Statistical analysis of costs
No statistical analysis of the quantities or costs was reported.
Indirect Costs
Productivity losses were measured in terms of days of sick leave. These were calculated using the age-dependent friction costs method and discounted at an annual rate of 4%. Details of the indirect cost data were presented in a supplementary web table.
The authors took the data from a single within-group comparison study. As they acknowledged, no causal relationship can be demonstrated from the use of this study design. No systematic search for other similar data was reported, which could be an important limitation. An important asset of the model was that the authors analysed a DMP adapted to the organisational context of the region and the longer term implications to a locally representative patient group, making the results more locally valid.
Validity of estimate of measure of benefit
The estimation of health benefits (QALYs) was modelled using a Markov model. The methods used to estimate the utility weights from the EQ-5D were not described in the paper. A reference to a web table was provided.
Validity of estimate of costs
Given the societal perspective reported, all the relevant cost categories and their associated costs appear to have been taken into consideration. The resource use data and unit costs were not reported in the paper, but the authors referenced a website for supplemental data and details. The price year and the sources of the unit costs and resource use were adequately reported. The costs were discounted at an annual rate of 4%, which would appear appropriate as the time horizon was greater than one year. Sensitivity analyses of the costs were conducted to assess the robustness of the estimates used. Another point that was not clear was that the measures of central tendency (i.e. mean, median) and dispersion (i.e. standard deviation, interquartile range) used for the base-case were not reported.
Other issues
The authors compared their findings with those from other studies and found their results, in general, to be in agreement. The authors stated some limitations of their study. For example, measurement periods of 3 months are somewhat prone to bias caused by seasonality or coincidental variation of parameters. Also, the missing values that mainly occurred within the follow-up period, thereby selectively affecting measures of the DMP, could be another source of potential bias. Finally, a common limitation as in all Markov models was that transition probabilities were considered to be constant over time, which in reality would not be the case. The authors stated that some strengths of the model were the PSA component and the use of the QALY construct as a generic measure of effectiveness, permitting its value to be assessed in a wider health care context. The authors' conclusions would appear to be an accurate reflection of the scope of their analysis.
Implications of the study
Although the authors stated that no causal relationship can be established due to the study design, they recommended implementing DMPs on a wider scale. However, decision-makers should analyse different programmes to look for the best fit of the DMP to the organisational scheme of the location or institution where it would be set up. More research should be performed to help the decision-making process and enhance the generalisability of the results. The application of decision analytic modelling techniques will help to achieve these goals.
